GlassScriptPhysician profile
Lloyd C Trommler
NPI 1417909458
$11,381.73
in general payments reported to CMS, 2019-2025
43 companies · $135 in 2025
The $135 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,374 · 2020: $1,156 · 2021: $2,657 · 2022: $3,053 · 2023: $2,415 · 2024: $592 · 2025: $135.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,142.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,142.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,847.98 | 2019-2024 | Qulipta, Vraylar, Ubrelvy |
| Astrazeneca Pharmaceuticals LP | $1,431.19 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Pfizer INC. | $769.97 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $733.43 | 2019-2023 | Spravato |
| Glaxosmithkline, LLC. | $569.39 | 2019-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Allergan, INC. | $543.56 | 2019-2020 | |
| Novo Nordisk INC | $525.96 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $493.79 | 2019-2024 | Mounjaro, Trulicity, Emgality |
| Amgen INC. | $443.06 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $419.70 | 2019-2023 | Camzyos, Eliquis |
| Sunovion Pharmaceuticals INC. | $354.98 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $299.81 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $278.85 | 2019-2023 | Tradjenta |
| Penumbra, INC. | $278.12 | 2022-2023 | Indigo System |
| Astellas Pharma US INC | $233.50 | 2019-2023 | Veozah |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lloyd Trommler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.